[HTML][HTML] Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
A Pardanani, JR Gotlib, C Jamieson… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
A Pardanani, JR Gotlib, C Jamieson, JE Cortes, M Talpaz, RM Stone, MH Silverman…
Journal of Clinical Oncology, 2011•ncbi.nlm.nih.govSafety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage
Main Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced
Search User Guide Journal List J Clin Oncol PMC4979099 Other Formats PDF (290K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles
Links to NCBI Databases Journal List J Clin Oncol PMC4979099 As a library, NLM provides …
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage
Main Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced
Search User Guide Journal List J Clin Oncol PMC4979099 Other Formats PDF (290K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles
Links to NCBI Databases Journal List J Clin Oncol PMC4979099 As a library, NLM provides …
Abstract
Purpose
Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms. Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor.
ncbi.nlm.nih.gov